Clinical Trials

900 enrolled

Prostatic Neoplasms

NCT05818683 2026-04-13

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

300 enrolled

Metastatic Castration-resistant Prostate Neoplasms

NCT06136624 2026-04-08

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT07287150 2026-04-08

InavoPC

100 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

599 enrolled

Prostatic Neoplasms

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

49 enrolled

Neoplasms

NCT06120491 2026-04-03

EvoPAR-PR01

1,800 enrolled

Prostatic Neoplasms

NCT03899155 2026-04-01

Pan Tumor Rollover Study

1,500 enrolled

Neoplasms

NCT04221542 2026-03-30

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

479 enrolled

Bites and Stings, Prostatic Neoplasms

NCT07028853 2026-03-30

MEVPRO-3

1,000 enrolled

Prostatic Neoplasms

NCT04191096 2026-03-20

KEYNOTE-991

1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05526248 2026-03-11

ARAMON

Phase 2 Completed

28 enrolled 14 charts

Biochemically Recurrent Prostate Cancer

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT06691984 2026-03-06

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

675 enrolled

Neoplasms, Prostatic Neoplasms

NCT07230106 2026-03-03

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

218 enrolled

Prostatic Neoplasms

NCT06257693 2026-02-27

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

56 enrolled

Prostate Adenocarcinoma

NCT06855277 2026-02-24

AcTFirst

940 enrolled

Prostatic Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

1,200 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Metastatic Castration-Resistant Prostate Cancer

NCT05551117 2026-02-09

Tamarack

Phase 2 Terminated

192 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

174 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT03768063 2026-01-29

IMbrella B

1,000 enrolled

Neoplasms

NCT06764485 2026-01-28

rechARge

960 enrolled

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02003924 2026-01-27

PROSPER

1,401 enrolled 25 charts

Prostatic Neoplasms

NCT03338790 2026-01-27

CheckMate 9KD

Phase 2 Completed

292 enrolled 21 charts

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

455 enrolled 18 charts

Prostatic Neoplasms

NCT07277270 2026-01-07

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

84 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT06228053 2025-12-22

SYNERGY-201

53 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05367440 2025-12-08

PETRANHA

174 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Prostatic Neoplasms

NCT05914116 2025-11-21

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

862 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT05252390 2025-11-06

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

82 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT03480646 2025-10-29

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Completed

175 enrolled 23 charts

Neoplasms

NCT02294461 2025-10-24

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

395 enrolled 25 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02677896 2025-10-24

ARCHES

1,150 enrolled 23 charts 1 FDA

Metastatic Hormone Sensitive Prostate Cancer

NCT03939689 2025-10-14

ARROW

Phase 2 Completed

120 enrolled 21 charts

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1/2 Terminated

65 enrolled

Bites and Stings

NCT04557449 2025-10-01

CDK4i

362 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT04934722 2025-10-01

KEYNOTE-991

Phase 1/2 Not yet recruiting

186 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT07198633 2025-09-30

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

212 enrolled